EQL Pharma AB is a Sweden-based Company that operates as a generic drugs and specialty pharmaceutical company. The Company engages in marketing, distributing, and selling generic drugs and specialty pharmaceuticals. Its main products are Anastrozol, Venlafaxin, Carvedilol, Metformin, Sumatriptan, Mometason, Glepark, among others. The company operates in Sweden and in Scandinavia.

Employees

Sector

Drug Retailers

Calendar

11-05 Earnings release - Q2 2027

More about the company

Quotes

Date	Price	Change	Volume
26-09-29	SEK 23.00	0.00%	18,375
26-09-28	SEK 23.00	-1.71%	14,806
26-09-25	SEK 23.40	+1.74%	4,594
26-09-24	SEK 23.00	-1.50%	3,093
26-09-23	SEK 23.35	+0.65%	10,249

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm 12:00:00 2026-09-29 EDT			5-day change	1st Jan Change
23.00 ^SEK	0.00%		-1.71%	-60.21%

08-20	EQL Pharma AB Appoints Niraj Kumar as New Board Member	CI
08-17	EQL Pharma CFO Allan Sylvest Aasberg makes his first share purchase	FW

Market Cap	679M 67.8M 59.84M 56.62M 51.34M 96.26M 6.51B 97.21M 262M 3.32B 255M 249M 10.69B	P/E 2027 *	-	P/E 2028 *	9.62x
Enterprise Value	1.1B 109M 96.58M 91.38M 82.87M 155M 10.5B 157M 422M 5.36B 411M 402M 17.26B	EV / Sales 2027 *	2.25x	EV / Sales 2028 *	1.81x
Free-Float	42.3%	Yield 2027 *	-	Yield 2028 *	-

Markets		Quality
Nasdaq Stockholm	EQL	Delayed
Deutsche Boerse AG	7JK	End-of-day quote
Deutsche Boerse AG	7JK	Delayed
Börse Stuttgart	7JK	Delayed
Boerse Muenchen	7JK	Real-time

08-20	EQL Pharma AB Appoints Niraj Kumar as New Board Member	CI
08-17	EQL Pharma CFO Allan Sylvest Aasberg makes his first share purchase	FW
08-14	DNB Carnegie raises its justified value for EQL Pharma	FW
08-12	EQL Pharma Enters UTI Treatment License Deal in Hungary	MT
08-12	EQL Pharma: Analysguiden cuts fair value estimate to 38 kronor	FW
08-12	EQL Pharma licenses Memprex to partner in Hungary	FW
08-12	EQL Pharma AB Licenses Memprex for Sale in Hungary	CI
08-07	EQL Pharma AB, Q1 2027 Earnings Call, Aug 07, 2026
08-07	EQL Pharma AB Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
08-07	EQL Pharma swings to an operating loss, 'going through a tough period' - CEO (update)	FW
08-07	EQL Pharma swings to an operating loss, 'going through a tough period' - CEO	FW
08-07	Eql Pharma AB Provides Earnings Guidance for the Year 2026/27	CI
07-28	DNB Carnegie cuts justified value for EQL Pharma	FW

EQL Pharma AB Stock

Stocks

EQL

SE0005497732

Drug Retailers

Valuation: EQL Pharma AB

Chart: EQL Pharma AB

Latest news: EQL Pharma AB

Last Transcript: EQL Pharma AB

Analysts' recommendations: EQL Pharma AB

Press Releases: EQL Pharma AB

Quotes and Performance

Price Extremes

Managers and Directors: EQL Pharma AB

Latest insider transactions

Other Drug Retailers

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

08-20	Bulletin from the annual general meeting in EQL Pharma AB on 20 August 2026	AQ
08-14	EQL Pharma: Improvement emerging, confirmation needed – Q1 review	AQ
08-12	Memprex© (methenamine hippurate) license signed with partner for Hungary	AQ
08-07	EQL Pharma: Soft start as expected, guidance intact	AQ
08-07	Interim Report April - June 2026	AQ

1 week	-1.71%
Current month	-14.97%
1 month	-11.54%
3 months	-2.54%
6 months	-54.72%
Current year	-60.21%

1 week	22.5	24
1 month	22.2	28.15
Current year	17.38	67.5
1 year	17.38	68.6
3 years	17.38	98.6
5 years	17.38	98.6
10 years	6.35	98.6

Manager	Title	Age	Since
Axel Schörling CEO	Chief Executive Officer	40	2022-08-16
Allan Sylvest Aasberg DFI	Director of Finance/CFO	51	2026-03-31
Martin Kristofferson COO	Chief Operating Officer	48	2022-08-16

Director	Title	Age	Since
Lars Christer Fedrik Fåhraeus CHM	Chairman	61	2022-08-16
Anders Månsson CHM	Chairman	59	-
Ingrid Linda Marie Neckmar BRD	Director/Board Member	53	2019-12-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
8/14/26	Allan Sylvest Aasberg	Buy	Chief Financial Officer	20,000	0.0677%
3/27/26	Axel Schörling	Sell	Chief Executive Officer	24,066	0.0815%
12/30/25	Magnus Erreth	Buy	Executive/Senior Manager	1,000	0.0034%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EQL PHARMA AB	0.00%	-1.71%	-67.10%	-13.86%	68.21M
JD HEALTH INTERNATIONAL INC.	+1.41%	-0.83%	-44.12%	-4.28%	14.45B
MATSUKIYOCOCOKARA & CO.	-1.30%	-4.01%	-21.26%	-9.24%	6.22B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-0.53%	-3.58%	-54.51%	-35.94%	5.85B
YIFENG PHARMACY CHAIN CO., LTD.	+2.40%	+3.88%	-7.29%	-21.27%	4.06B
NAHDI MEDICAL COMPANY	-0.27%	-1.89%	-20.08%	-36.93%	3.16B
CLICKS GROUP LIMITED	+1.04%	+3.25%	-39.97%	-16.71%	3.03B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	+0.34%	-0.67%	+4.21%	-29.11%	3.01B
GUARDIAN PHARMACY SERVICES, INC.	-0.15%	-8.93%	+56.04%	-	2.58B
CORPORATIVO FRAGUA, S.A.B. DE C.V.	-2.02%	-2.01%	-29.89%	-14.22%	2.25B
Average	+0.09%	-1.25%	-22.40%	-20.17%	4.47B
Weighted average by Cap.	+0.39%	-1.42%	-27.25%	-16.72%

	2027 *	2028 *
Net sales	486M 48.57M 42.86M 40.55M 36.78M 68.95M 4.66B 69.63M 187M 2.38B 182M 178M 7.66B	612M 61.15M 53.96M 51.06M 46.3M 86.81M 5.87B 87.67M 236M 3B 230M 225M 9.64B
Net income	-	71M 7.09M 6.26M 5.92M 5.37M 10.06M 680M 10.16M 27.36M 347M 26.62M 26.04M 1.12B
Net Debt	417M 41.63M 36.74M 34.76M 31.52M 59.1M 3.99B 59.69M 161M 2.04B 156M 153M 6.56B	430M 42.93M 37.88M 35.84M 32.51M 60.94M 4.12B 61.55M 166M 2.1B 161M 158M 6.77B